BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38679289)

  • 1. Treatment Effect Waning Assumptions: A Review of National Institute of Health and Care Excellence Technology Appraisals.
    Trigg LA; Melendez-Torres GJ; Abdelsabour A; Lee D
    Value Health; 2024 Apr; ():. PubMed ID: 38679289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the assumption of waning of treatment effect applied consistently across NICE technology appraisals? A case-study focusing on disease-modifying therapies for treatment of multiple sclerosis.
    Armoiry X; Wang-Steverding X; Connock M; Grove A; Clarke A; Arun T; Counsell C; Auguste P
    Int J Technol Assess Health Care; 2022 Dec; 38(1):e83. PubMed ID: 36510406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
    Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
    Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
    Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
    Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
    Gallacher D; Auguste P; Connock M
    Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-sectional analysis of use of real-world data in single technology appraisals of oncological medicine by the National Institute for Health and Care Excellence in 2011-2021.
    Kang J; Cairns J
    BMJ Open; 2024 Mar; 14(3):e077297. PubMed ID: 38485485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE).
    Leahy TP; Ramagopalan S; Sammon C
    BMC Health Serv Res; 2020 Jul; 20(1):675. PubMed ID: 32698805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy.
    Kang J; Cairns J
    BMC Cancer; 2022 Dec; 22(1):1268. PubMed ID: 36471259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement.
    Bell Gorrod H; Kearns B; Stevens J; Thokala P; Labeit A; Latimer N; Tyas D; Sowdani A
    Med Decis Making; 2019 Nov; 39(8):899-909. PubMed ID: 31707911
    [No Abstract]   [Full Text] [Related]  

  • 13. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
    Tosh JC; Longworth LJ; George E
    Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy.
    Kang J; Cairns J
    BMJ Open; 2022 Jan; 12(1):e055985. PubMed ID: 34992121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Audit of data redaction practices in NICE technology appraisals from 1999 to 2019.
    Osipenko L
    BMJ Open; 2021 Oct; 11(10):e051812. PubMed ID: 34615680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of quality of data submitted for NICE technology appraisals over two decades.
    Osipenko L; Ul-Hasan SA; Winberg D; Prudyus K; Kousta M; Rizoglou A; Rustignoli I; van der Maas L
    BMJ Open; 2024 Feb; 14(2):e074341. PubMed ID: 38351112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals.
    Polak TB; Cucchi DGJ; van Rosmalen J; Uyl-de Groot CA
    BMJ Open; 2022 Jan; 12(1):e052186. PubMed ID: 34992108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. It's not evidence, it's insight: bringing patients' perspectives into health technology appraisal at NICE.
    Staley K; Doherty C
    Res Involv Engagem; 2016; 2():4. PubMed ID: 29062505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
    Schaefer R; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
    [No Abstract]   [Full Text] [Related]  

  • 20. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
    Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
    Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.